skip to main content

Biologic Immunogenicity Prevention — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardRheumatoid ArthritisBiologic Immunogenicity PreventionSCE Rheumatology

A 50-year-old woman with RA on Adalimumab monotherapy (without Methotrexate due to intolerance) develops secondary loss of response at 18 months. Anti-drug antibodies are elevated. What strategy reduces immunogenicity when using anti-TNF monoclonal antibodies?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Concomitant Methotrexate (or other immunomodulator) significantly reduces anti-drug antibody formation and improves biologic drug levels and clinical response

Concomitant Methotrexate reduces immunogenicity of monoclonal antibody biologics by suppressing the adaptive immune response that generates anti-drug antibodies. The CONCERTO trial demonstrated a dose-response effect: even low-dose Methotrexate (10 mg weekly) significantly reduced Adalimumab immunogenicity. BSR guidelines recommend combining Methotrexate with monoclonal anti-TNF agents wherever possible. For patients intolerant of Methotrexate alternatives include Leflunomide or low-dose Azathioprine as immunomodulators. Etanercept (a fusion protein) has lower immunogenicity than monoclonal antibodies and can be used more effectively as monotherapy.

Reference: BSR 2019 biologic safety guidelines; Burmester GR et al 2015 CONCERTO trial